DOCSLIB.ORG

SCHEDULE of EVENTS Saturday, April 6 All Sessions Eligible for CME Credit Unless Otherwise Noted.*

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
SCHEDULE of EVENTS Saturday, April 6 All Sessions Eligible for CME Credit Unless Otherwise Noted.* 09_13AM_SchedEvents_Layout 1 3/15/13 9:14 AM Page 89 SCHEDULE OF EVENTS Saturday, April 6 All sessions eligible for CME credit unless otherwise noted.* Saturday, April 6, 2013 The Next Frontier in Targeted Therapy for Melanoma, Martin McMahon, Chairperson, Room 144, Washington Convention Center, p. 133 8:00 a.m.-10:00 a.m. Educational Sessions Speakers: Martin McMahon, Jedd D. Wolchok, Lynda Chin, Keiran S. Smalley Cancer Genomics in the Clinic: Methods and Lessons Learned , John D. Carpten, Chairperson, Room 147, PARP Inhibitors in Cancer Therapy, Ralph Scully, Washington Convention Center, Chairperson, Room 146, Washington Convention Center, p. 131 p. 134 Speakers: Olli P. Kallioniemi, Josep Tabernero, David Craig, Speakers: Ralph Scully, Thomas Helleday, Judy E. Garber, Javed Khan Mark J. O’Connor Cancer Prognosis and Survivorship: Novel Strategies Tumor Immunology and Immunotherapy for Non- and Results , Cornelia M. Ulrich, Chairperson, Room 103, Immunologists, Suzanne Ostrand-Rosenberg, Chairperson, Washington Convention Center, p. 131 Room 202, Washington Convention Center, p. 134 Speakers: Thomas J. Hudson, Cornelia M. Ulrich, Lee Speakers: Arthur A. Hurwitz, Cassian Yee, Anna K. Palucka, Jones, Paul B. Jacobsen Louis M. Weiner Epithelial Stem Cells, Morphogenesis, and Cancer , Tumor-Secreted Factors, David C. Lyden, Chairperson, Ian G. Macara, Chairperson, Room 151, Washington Room 152, Washington Convention Center, p. 135 Convention Center, p. 132 Speakers: Zena Werb, David C. Lyden, Xandra O. Speakers: Ian G. Macara, Robert J. Coffey, Lindsay Hinck, Breakefield, George A. Calin Senthil K. Muthuswamy Whole Body Metabolism and Cancer, Philipp E. Scherer, From Chemistry to the Clinic: Pathways for Drug Chairperson, Ballroom A-B, Washington Convention Center, Discovery and Development, Part 1: Targeting p. 135 Mechanisms of Therapeutic Resistance, Matt V. Lorenzi, Chairperson, Room 207, Washington Convention Center, Speakers: Philipp E. Scherer, Thomas N. Seyfried, Anne p. 132 McTiernan, M. Celeste Simon Speakers: Matt V. Lorenzi, Kwok-Kin Wong, Ross L. Levine, Thomas F. Gajewski 8:00 a.m.-10:00 a.m. Methods Workshops Functional Assessment of Actionable Mutations in Breast Cancer, Ron Bose, Chairperson, Room 145, Washington Convention Center, p. 133 Cancer Methylomes for Biomarker and Pathway Discovery, Toshikazu Ushijima, Chairperson, Room 143, Speakers: Heidi Greulich, Ron Bose, Samuel Aparicio, Washington Convention Center, p. 136 Chad Creighton Speakers: Toshikazu Ushijima, Stephan Beck, Christoph Bock, Chuan He April 6-10, 2013 | Washington, DC 89 09_13AM_SchedEvents_Layout 1 3/15/13 9:14 AM Page 90 SCHEDULE OF EVENTS All sessions eligible for CME credit unless otherwise noted.* Computational Methods in Molecular Epidemiology, Clonal Evolution of Cancer, Matthew J. Walter, Kimberly D. Siegmund, Chairperson, Room 150, Chairperson, Ballroom C, Washington Convention Center, Washington Convention Center, p. 136 p. 139 Speakers: Montserrat Garcia-Closas, Kimberly D. Speakers: Carlo C. Maley, Matthew J. Walter, Catherine J. Siegmund, Li Hsu, Debashis Ghosh Wu, Charles Swanton Techniques for Assessing Circulating Tumor Cells, Endocrine Resistance in Breast Cancer, Nancy E. Circulating DNA, and microRNAs, Sanjiv S. Gambhir, Davidson, Chairperson, Room 103, Washington Convention Chairperson, Ballroom C, Washington Convention Center, Center, p. 140 p. 137 Speakers: Nancy E. Davidson, Matthew P. Goetz, Steffi Speakers: Maximilian Diehn, Muneesh Tewari, Caroline Oesterreich, Douglas Yee Dive, Peter Kuhn Epigenetic Regulators in Hematology: From Stem Cells to Malignancies, Ross L. Levine, Chairperson, Room 147, 9:00 a.m.-3:00 p.m. Career Fair Washington Convention Center, p. 140 Speakers: Guy Sauvageau, Anwesha Dey, Guido Marcucci Cancer and Biomedical Research Career Fair*, Salons ABC, East Hall, Washington Convention Center, p. 138 From Chemistry to the Clinic: Pathways for Drug Discovery and Development, Part 2: Targeting Epigenetics: An Epicenter of Oncology Drug Discovery? 10:00 a.m.-12:00 p.m. Educational Session Ho Man Chan, Chairperson, Room 207, Washington Convention Center, p. 141 Cancer Immunology for the Non-Immunologist - Tutorial, Speakers: Ho Man Chan, Russell J. H. Ryan, Jinrong Min, Michael A. Caligiuri, Chairperson, Room 206, Washington Dashyant Dhanak Convention Center, p. 138 Faculty: Mario P. Colombo, Julie Y. Djeu, Olivera J. Finn, Future Directions in Personalized Medicine for Lung John G. Frelinger, Wolf H. Fridman, Arthur A. Hurwitz, Hyam Cancer I. Levitsky, Suzanne Ostrand-Rosenberg, Anna K. Palucka, , Tony S. Mok, Chairperson, Room 143, Washington Elizabeth A. Repasky, Suzanne L. Topalian, Louis M. Weiner, Convention Center, p. 141 Cassian Yee, Weiping Zou Speakers: Vincent A. Miller, Tony S. Mok, Pasi A. Jänne, Johan F. Vansteenkiste 10:15 a.m.-12:15 p.m. Educational Sessions Immune Modulation in the Tumor Microenvironment: Tregs and Other Factors Regulating Host Response, James P. Allison, Chairperson, Room 145, Washington Clinical Trial Design in the Genomic Era, Donald A. Berry Convention Center, p. 142 and George W. Sledge, Co-Chairpersons, Room 146, Washington Convention Center, p. 139 Speakers: Raghu Kalluri, Tyler Curiel, James P. Allison Speakers: George W. Sledge, Charles M. Perou, Donald A. Berry 90 AACR Annual Meeting 2013 09_13AM_SchedEvents_Layout 1 3/15/13 9:14 AM Page 91 Saturday, April 6 Metabolism and Signaling in Cancer, Eyal Gottlieb, Patient-Derived Xenograft Models of Cancer: Where Are Chairperson, Ballroom A-B, Washington Convention Center, We Going? Matthew J. Ellis, Chairperson, Room 204, p. 142 Washington Convention Center, p. 146 Speakers: Eyal Gottlieb, Almut Schulze, David M. Sabatini, Speakers: Michael T. Lewis, Jeremy N. Rich, Tan A. Ince, Nika Danial Matthew J. Ellis New Approaches in Molecular Epidemiology, Carmen J. Stem Cells, Enteroids, and Organoids: A New Era for In Marsit, Chairperson, Room 152, Washington Convention Vitro Models of the Intestine, James M. Wells, Center, p. 143 Chairperson, Room 201, Washington Convention Center, p. 146 Speakers: Marylyn D. Ritchie, Carmen J. Marsit, Heather H. Nelson, Bruce S. Kristal Speakers: James M. Wells, Toshiro Sato, Scott Magness, Calvin J. Kuo New Paradigms in Molecular Pharmacology, Angela N. Koehler, Chairperson, Room 151, Washington Convention Center, p. 143 10:30 a.m.-4:00 p.m. Professional Speakers: Angela N. Koehler, James E. Bradner, Andrew J. Advancement Session Phillips, Arturo J. Vegas Eighth Annual Undergraduate Student Caucus and Therapeutic Nanotechnology, Gregory Lanza, Poster Competition*, Kathleen W. Scotto, Chairperson, Chairperson, Room 144, Washington Convention Center, Grand Ballroom North, Renaissance Washington Hotel, p. 144 p. 147 Speakers: Omid C. Farokhzad, Esther H. Chang, Thomas L. Speakers: Donald S. Coffey, José Baselga Andresen, Gregory Lanza 12:00 p.m.-5:00 p.m. Professional 10:15 a.m.-12:15 p.m. Methods Workshops Advancement Session Advances in High-Resolution Optical Microscopy, Jan T. 16th Annual Grant Writing Workshop*, Congressional Hall Liphardt, Chairperson, Room 150, Washington Convention A-B, Renaissance Washington Hotel, p. 148 Center, p. 145 Speakers: Wei Zheng, Karen E. Knudsen, Victoria L. Speakers: Jan T. Liphardt, Jay T. Groves, Alan R. Lowe, Seewaldt Schuyler van Engelenburg Mock Study Session Chairperson: Bernard E. Weissman Cancer Omics Beyond the Genome, Keji Zhao, Category Codes for Poster Sessions and Minisymposia Chairperson, Room 202, Washington Convention Center, MCB = Molecular and Cellular Biology; MD = Multidisciplinary 1; CG = Carcinogenesis; CH = Cancer Chemistry; CL = Clinical Research; p. 145 EN = Endocrinology; EP = Epidemiology; ET = Experimental and Speakers: X. Sunny Xie, Benjamin P. Berman, Keji Zhao, Molecular Therapeutics; IM = Immunology; PR = Prevention Research; TB = Tumor Biology Nicholas Ingolia April 6-10, 2013 | Washington, DC 91 09_13AM_SchedEvents_Layout 1 3/15/13 9:14 AM Page 92 SCHEDULE OF EVENTS All sessions eligible for CME credit unless otherwise noted.* 1:00 p.m.-3:00 p.m. Educational Sessions Hypoxia-Induced Metastasis, M. Celeste Simon, Chairperson, Ballroom C, Washington Convention Center, p. 153 The Central Role of the Microenvironment in Initiation Speakers: Randall Johnson, Richard Bruick, Amato J. and Progression of Tumors and Response to Giaccia, M. Celeste Simon Chemotherapy, Mina J. Bissell, Chairperson, Room 143, Washington Convention Center, p. 149 Speakers: Frances R. Balkwill, Shahin Rafii, Mina J. Bissell, Noncoding RNAs in Cancer: From Pathogenesis to Larry Norton Therapeutics, Elsa R. Flores, Chairperson, Room 145, Washington Convention Center, p. 153 Speakers: Elsa R. Flores, Carlo M. Croce, Andrea Ventura, Change for the Worse: Premalignant Metaplasia in the Michael F. Clarke Stomach, Esophagus, and Pancreas, Steven D. Leach, Chairperson, Room 201, Washington Convention Center, p. 150 p53: Still Controversial after All These Years, Carol L. Speakers: James R. Goldenring, Jason A. Mills, Anil K. Prives, Chairperson, Room 147, Washington Convention Rustgi, Steven D. Leach Center, p. 154 Speakers: Carol L. Prives, Wei Gu, Karen H. Vousden, Moshe Oren Credentialing Response Biomarkers for Signal Transduction Inhibitors, Neal Rosen, Chairperson, Room 204, Washington Convention Center, p. 150 Translational Cancer Research for the Basic Scientist, Speakers: Anthony G. Letai, Ravi K. Amaravadi, Neal Rosen Christos Sotiriou, Chairperson, Room 152, Washington Convention Center, p. 154 Speakers: Christos Sotiriou, Britta
Load more

Recommended publications
  • NCI RAS Initiative Update
    Ras Initiative Update Frank McCormick and Levi Garraway DEPARTMENT OF HEALTH AND HUMAN SERVICES • National Institutes of Health • National Cancer Institute The Frederick National Laboratory is a Federally Funded Research and Development Center operated by Leidos Biomedical Research, Inc., for the National Cancer Institute RAS Initiative Accomplishments: Evaluating Ras dependency 2 SiREN assay for Ras dependency SiREN assay for Ras dependency 70% KD siEGFP 0-10% KD 50% KD 100% KD SiREN assay for Ras dependency RAS Initiative Accomplishments: Biophysical and structural analysis 7 Ras proteins 1 -166 167-185,6 Raf, PI 3’ kinase RalGDS, GAPs Raf, PI 3’ kinase RalGDS, GAPs Raf, PI 3’ kinase RalGDS, GAPs Raf, PI 3’ kinase RalGDS, GAPs Palmitoyl Farnesyl Fully processed KRAS4b A. Gorfe, U-Texas Houston Engineering baculovirus for improved production of processed KRAS • recombineering used to insert FNTA/FNTB genes into the baculovirus genome • eliminated issues with coinfection of multiple viruses • maltose-binding protein (MBP) fusion for greater yield and solubility • Trichoplusia ni (Hi5) insect cells for increased yield Carissa Grose, Dom Esposito, Bill Gillette Processed KRAS4b characterization • Extensive protein characterization – Purified to homogeneity; yield >7mg/L – Intact mass – Predominantly monomeric – Secondary structure equivalent to non-processed KRAS4b KRAS4b- FME – Lower thermal stability Intact mass analysis Analytical ultracentrifugation Secondary structure by CD 2.14 S 25.7 kDa 10 Bill Gillette, Zhaojing Meng, Shelley Perkins,
    [Show full text]
  • Miriam Molina Arcas
    CV Miriam Molina Arcas Miriam Molina Arcas Principal Laboratory Research Scientist The Francis Crick Institute 1 Midland Road, NW1 1AT London +442037963313 [email protected] EDUCATION 1999-2005 PhD in Biomedicine, University of Barcelona, Spain Role of equilibrative nucleoside transporters in the sensitivity to antineoplasic drugs. Supervisors: Prof. Marçal Pastor-Anglada and Dr. F. Javier Casado 1994-1999 BSc Biochemistry, University of Barcelona, Spain RESEARCH AND PROFESSIONAL EXPERIENCE June 2016- present Senior Laboratory Research Scientist, Oncogene Biology Laboratory, The Francis Crick Institute. Prof. Julian Downward. Studied combination approaches that improve the efficacy of KRAS inhibitors and reduce resistance mechanisms. March 2015- May 2016 Postdoctoral Fellow, Lung Cancer Team, Institute of Cancer Research. Prof. Julian Downward. Designed and optimized a whole-genome shRNA screen to identify synthetic lethal interactions with MEK and IGF1R inhibitors. Sep 2008- Feb 2015 Postdoctoral Fellow, Signal Transduction Laboratory, Cancer Research UK- London Research Institute. Prof. Julian Downward Using RNA interfering and drug screens, identified new therapeutic strategies to treat tumours harbouring KRAS mutations 2006- Aug 2008 Postdoctoral Fellow, University of Barcelona, Spain Prof. Marçal Pastor-Anglada Studied the role of membrane transporters in nucleoside-derived drug response in cancer and HIV. TEACHING AND MENTORING EXPERIENCE 2018-2021 Honorary Research Associate in the School of Life & Medical Sciences, University College London, part of the Certificate in Core Teaching Practices. 2007-2008 Part-time lecturer of Biochemistry and Molecular Biology (University of Barcelona). 180h of theory and practical lessons. 2003-2005 Teaching assistant of Biochemistry and Molecular Biology (University of Barcelona). 60h of practical lessons. September 2019 Co-supervisor of MSc Experimental Pharmacology and Therapeutics Research of Pablo Romero Clavijo at the University College London.
    [Show full text]
  • Female Fellows of the Royal Society
    Female Fellows of the Royal Society Professor Jan Anderson FRS [1996] Professor Ruth Lynden-Bell FRS [2006] Professor Judith Armitage FRS [2013] Dr Mary Lyon FRS [1973] Professor Frances Ashcroft FMedSci FRS [1999] Professor Georgina Mace CBE FRS [2002] Professor Gillian Bates FMedSci FRS [2007] Professor Trudy Mackay FRS [2006] Professor Jean Beggs CBE FRS [1998] Professor Enid MacRobbie FRS [1991] Dame Jocelyn Bell Burnell DBE FRS [2003] Dr Philippa Marrack FMedSci FRS [1997] Dame Valerie Beral DBE FMedSci FRS [2006] Professor Dusa McDuff FRS [1994] Dr Mariann Bienz FMedSci FRS [2003] Professor Angela McLean FRS [2009] Professor Elizabeth Blackburn AC FRS [1992] Professor Anne Mills FMedSci FRS [2013] Professor Andrea Brand FMedSci FRS [2010] Professor Brenda Milner CC FRS [1979] Professor Eleanor Burbidge FRS [1964] Dr Anne O'Garra FMedSci FRS [2008] Professor Eleanor Campbell FRS [2010] Dame Bridget Ogilvie AC DBE FMedSci FRS [2003] Professor Doreen Cantrell FMedSci FRS [2011] Baroness Onora O'Neill * CBE FBA FMedSci FRS [2007] Professor Lorna Casselton CBE FRS [1999] Dame Linda Partridge DBE FMedSci FRS [1996] Professor Deborah Charlesworth FRS [2005] Dr Barbara Pearse FRS [1988] Professor Jennifer Clack FRS [2009] Professor Fiona Powrie FRS [2011] Professor Nicola Clayton FRS [2010] Professor Susan Rees FRS [2002] Professor Suzanne Cory AC FRS [1992] Professor Daniela Rhodes FRS [2007] Dame Kay Davies DBE FMedSci FRS [2003] Professor Elizabeth Robertson FRS [2003] Professor Caroline Dean OBE FRS [2004] Dame Carol Robinson DBE FMedSci
    [Show full text]
  • The Ubiquitin Proteasome System and Its Involvement in Cell Death Pathways
    Cell Death and Differentiation (2010) 17, 1–3 & 2010 Macmillan Publishers Limited All rights reserved 1350-9047/10 $32.00 www.nature.com/cdd Editorial The ubiquitin proteasome system and its involvement in cell death pathways F Bernassola1, A Ciechanover2 and G Melino1,3 Cell Death and Differentiation (2010) 17, 1–3; doi:10.1038/cdd.2009.189 Following the awarding of the 2004 Nobel Prize in Chemistry Inactivation of the proteasome following caspase-mediated to Aaron Ciechanover, Avram Hershko, and Irwin A Rose cleavage may disable the proteasome, interfering with its for the discovery of ubiquitin (Ub)-mediated degradation, role in the regulation of key cellular processes and thereby Cell Death and Differentiation has drawn the attention of facilitating induction of apoptosis. The noted recent develop- its readers to the Ub Proteasome System (UPS) and its ments show how understanding of these functions is just involvement in regulating cell death pathways.1–4 The current starting to emerge. For example, why does dIAP1 associate set of reviews is an update on this theme.5–16 with multiple E2s via its RING finger? Does dIAP1 also interact From previous review articles published in Cell Death and with the E3 – the F-box protein Morgue, which is a part of an Differentiation, it was apparent that the UPS has a major SCF E3 complex? Why does dIAP1, which is an E3, have to mechanistic role in regulating cell death via modification and interact with other ligases such as the N-end rule UBR1 and degradation of key regulatory proteins involved in
    [Show full text]
  • Unveiling New Disease, Pathway, and Gene Associations Via Multi-Scale Neural Networks
    Unveiling new disease, pathway, and gene associations via multi-scale neural networks Thomas Gaudelet 1, No¨elMalod-Dognin 2, Jon S´anchez-Valle 2, Vera Pancaldi 2,3,4, Alfonso Valencia 2,5,6 and NataˇsaPrˇzulj 2,5,∗ 1 Department of Computer Science, University College London, London, WC1E 6BT 2 Department of Life Sciences, Barcelona Supercomputing Center (BSC), Barcelona, 08034 Spain 3 Centre de Recherches en Canc´erologiede Toulouse (CRCT), UMR1037 Inserm, ERL5294 CNRS, 31037 Toulouse, France 4 University Paul Sabatier III, Toulouse, France 5 ICREA, Pg. Llu´ısCompanys 23, 08010 Barcelona, Spain 6 Coordination Node. Spanish National Bioinformatics Institute, ELIXIR-Spain (INB, ELIXIR-ES), Spain ∗ [email protected]. Abstract Diseases involve complex modifications to the cellular machinery. The gene expression profile of the affected cells contains characteristic patterns linked to a disease. Hence, new biological knowledge about a disease can be extracted from these profiles, improving our ability to diagnose and assess disease risks. This knowledge can be used for drug re-purposing, or by physicians to evaluate a patient's condition and co-morbidity risk. Here, we consider differential gene expressions obtained by microarray technology for patients diagnosed with various diseases. Based on these data and cellular multi-scale organization, we aim at uncovering disease{disease, disease{gene and disease{pathway associations. We propose a neural network with structure based on the multi- scale organization of proteins in a cell into biological pathways. We show that this model is able to correctly predict the diagnosis for the majority of patients. Through the analysis of the trained model, we predict disease{ disease, disease{pathway, and disease{gene associations and validate the predictions by comparisons to known interactions and literature search, proposing putative explanations for the predictions.
    [Show full text]
  • A Conversation with Karen Vousden
    A Conversation with Karen Vousden INTERVIEWER:JAN WITKOWSKI Executive Director, Banbury Center at Cold Spring Harbor Laboratory Karen Vousden is Director of the Cancer Research UK Beatson Institute. Jan Witkowski: Over the past few years, there’s been a tomography) imaging. It certainly is the case that many markedly increasing emphasis and interest in the metab- cancers have a high rate of glucose uptake, which is olism and biochemistry of cancers. It’s moving away what we measure when we do functional imaging, or a from just the genes and proteins. Am I right in thinking PET scan. that? However, over recent years our understanding of the Warburg effect has become more sophisticated, although Dr. Vousden: Yes, I think you’re absolutely right. we still don’t quite understand it. We know now that there There’s been a resurgence of interest in metabolism. In probably are changes in the metabolism of almost all the middle of the last century a lot of energy was spent on cancers. We’re interested in understanding that and then understanding metabolism and biochemists at this time asking, “Can we harness any of this information to were making huge progress. Many metabolic pathways develop new therapies?” were worked out in exquisite detail in the ’50s and the ’60s. Then came the oncogene revolution, and much of Jan Witkowski: Can you tell me a little about your the emphasis switched to understanding the regulation current work? of the cell cycle and signal transduction. At this point, metabolism was almost forgotten in cancer biology until Dr.
    [Show full text]
  • Fellows Opted out of the Mentoring Programme As of 21 July 2020 1 of 3 Professor Chris Abell FRS Fmedsci Professor Philip Jones
    Fellows opted out of the Mentoring programme as of 21 July 2020 Professor Chris Abell FRS FMedSci Professor Philip Jones FMedSci Professor David Adams FMedSci Professor Roger Jones FMedSci Professor Judith Allen FRSE FMedSci Professor Kamlesh Khunti FMedSci Professor Thomas Kirkwood CBE Professor Desmond Archer OBE FMedSci FMedSci Professor Louise Arseneault FMedSci Professor Robb Krumlauf FMedSci Professor Charalambos Kyriacou Professor Michael Arthur FMedSci FMedSci Professor Deborah Ashby OBE FMedSci Sir Peter Lachmann FRS FMedSci Professor Dame Frances Ashcroft DBE Professor Leon Lagnado FMedSci FRS FMedSci Professor Anthony Barrett FRS FMedSci Professor Ajit Lalvani FMedSci Professor Gillian Bates FRS FMedSci Professor Deborah Lawlor CBE FMedSci Professor Facundo Batista FMedSci Professor Joy Lawn FMedSci Professor Stephan Beck FMedSci Professor Susan Lea FMedSci Professor Jill Belch OBE FMedSci Professor Sir Robert Lechler PMedSci Professor Sir John Bell GBE FRS Dr Melanie Lee CBE FMedSci HonFREng FMedSci Professor Wendy Bickmore FRS FRSE Professor Andrew Lees FMedSci FMedSci Professor Sir Adrian Bird CBE FRS FRSE Professor Stafford Lightman FRS FMedSci FMedSci Professor Ewan Birney CBE FRS Professor Janet Lord FMedSci FMedSci Professor Dorothy Bishop FRS FBA Professor Thomas MacDonald FMedSci FMedSci Professor Rona MacKie CBE FRSE Professor Jane Blazeby FMedSci Sir Stephen Bloom FRS FMedSci Professor Giovanna Mallucci FMedSci Sir Tom Blundell FRS FMedSci Dr Fiona Marshall FMedSci Professor Dame Theresa Marteau DBE Professor Peter
    [Show full text]
  • 3718 Issue63july2010 1.Pdf
    Issue 63.qxd:Genetic Society News 1/10/10 14:41 Page 1 JULYJULLYY 2010 | ISSUEISSUE 63 GENETICSGENNETICSS SOCIETYSOCIEETY NENEWSEWS In this issue The Genetics Society NewsNewws is edited by U Genetics Society PresidentPresident Honoured Honoured ProfProf David Hosken and items ittems for future future issues can be sent to thee editor,editor, preferably preferably U Mouse Genetics Meeting by email to [email protected],D.J.Hosken@@exeter.ac.uk, or U SponsoredSponsored Meetings Meetings hardhard copy to Chair in Evolutionary Evoolutionary Biology, Biology, UniversityUniversity of Exeter,Exeter, Cornwall Cornnwall Campus, U The JBS Haldane LectureLecture Tremough,Tremough, Penryn, TR10 0 9EZ UK.UK. The U Schools Evolutionn ConferenceConference Newsletter is published twicet a year,year, with copy dates of 1st June andand 26th November.November. U TaxiTaxi Drivers The British YeastYeaste Group Group descend on Oxford Oxford for their 2010 meeting: m see the reportreport on page 35. 3 Image © Georgina McLoughlin Issue 63.qxd:Genetic Society News 1/10/10 14:41 Page 2 A WORD FROM THE EDITOR A word from the editor Welcome to issue 63. In this issue we announce a UK is recognised with the award of a CBE in the new Genetics Society Prize to Queen’s Birthday Honours, tells us about one of Welcome to my last issue as join the medals and lectures we her favourite papers by Susan Lindquist, the 2010 editor of the Genetics Society award. The JBS Haldane Mendel Lecturer. Somewhat unusually we have a News, after 3 years in the hot Lecture will be awarded couple of Taxi Drivers in this issue – Brian and seat and a total of 8 years on annually to recognise Deborah Charlesworth are not so happy about the committee it is time to excellence in communicating the way that the print media deals with some move on before I really outstay aspects of genetics research to scientific issues and Chris Ponting bemoans the my welcome! It has been a the public.
    [Show full text]
  • Drugging the Undruggable: Advances on RAS Targeting in Cancer
    G C A T T A C G G C A T genes Review Drugging the Undruggable: Advances on RAS Targeting in Cancer Miriam Molina-Arcas 1,*, Amit Samani 1,2,* and Julian Downward 1,3 1 Oncogene Biology Laboratory, Francis Crick Institute, London NW1 1AT, UK; [email protected] 2 Department of Medical Oncology, Imperial College Healthcare NHS Trust, London W2 1NY, UK 3 Lung Cancer Group, Institute of Cancer Research, London SW3 6JB, UK * Correspondence: [email protected] (M.M.-A.); [email protected] (A.S.) Abstract: Around 20% of all malignancies harbour activating mutations in RAS isoforms. Despite this, there is a deficiency of RAS-targeting agents licensed for therapeutic use. The picomolar affinity of RAS for GTP, and the lack of suitable pockets for high-affinity small-molecule binding, precluded effective therapies despite decades of research. Recently, characterisation of the biochemical properties of KRAS-G12C along with discovery of its ‘switch-II pocket’ have allowed development of effective mutant-specific inhibitors. Currently seven KRAS-G12C inhibitors are in clinical trials and sotorasib has become the first one to be granted FDA approval. Here, we discuss historical efforts to target RAS directly and approaches to target RAS effector signalling, including combinations that overcome limitations of single-agent targeting. We also review pre-clinical and clinical evidence for the efficacy of KRAS-G12C inhibitor monotherapy followed by an illustration of combination therapies designed to overcome primary resistance and extend durability of response. Finally, we briefly discuss novel approaches to targeting non-G12C mutant isoforms.
    [Show full text]
  • GSA Welcomes 2012 Board Members
    7INTERs3PRING 4HE'3!2EPORTER winter s spring 2012 New Executive GSA Welcomes 2012 Board Members Director Now on Board The Genetics Society of America New Members of the GSA Board of welcomes four new members elected Directors Adam P. Fagen, by the general membership to the Ph.D., stepped in as 2012 GSA Board of Directors. The VICE PRESIDENT: GSA’s new Executive new members are: Michael Lynch Michael Lynch, Director beginning (Indiana University), who serves as Distinguished December 1, 2011. vice president in 2012 and as GSA Professor of Dr. Fagen previously president in 2013 and Marnie E. Biology, Class of was at the American Halpern (Carnegie Institution for 1954 Professor, Society of Plant Science); Mohamed Noor (Duke Department of Biologists (ASPB), University); and John Schimenti Biology, Indiana where he was the director of public (Cornell University), who will serve as University, continued on page nineteen directors. Bloomington. Dr. Lynch is a population and evolutionary biologist and a In addition to these elected officers, long-time member of GSA. Dr. Lynch 2012 Brenda J. Andrews (University of sees GSA as the home for geneticists Toronto), Editor-in-Chief of GSA’s who study a broad base of topics GSA Award journal, G3: Genes|Genomes|Genetics, and organisms, and as a forum Recipients which was first published online in where general discussion occurs, June 2011, becomes a member of the whether based on the principles Announced Board of Directors. The bylaws have of genetics, the most pressing historically included the GENETICS GSA is pleased to announce the issues within the discipline itself, or editor-in-chief on the Board and as a responses to societal concerns and/ 2012 recipients of its five awards result of a 2011 bylaw revision, the G3 for distinguished service in the or conflicts within applied genetics.
    [Show full text]
  • IST Annual Report 2019
    Annual Report 2019 IST Austria administrative and The people of IST Austria technical support staff by nationality Austria 59.4% Nationalities on campus Germany 5.6% Hungary 3.1% Poland 2.5% Romania 2.5% Scientists as well as administrative and technical support staff come Italy 2.1% Russia 1.7% from all over the world to conduct and back research at IST Austria. Czech Republic 1.4% As of December 31, 2019, a total of 72 nationalities were represented India 1.4% Slovakia 1.4% on campus. Spain 1.4% UK 1.4% Other 16.1% North America Europe Asia Canada Albania Italy Afghanistan Cuba Andorra Latvia Bangladesh El Salvador Armenia Lithuania China Mexico Austria Luxembourg South Korea USA Belarus Macedonia India Belgium Malta Iran Bosnia and Netherlands Israel Herzegovina Norway Japan Bulgaria Poland Jordan Croatia Portugal Kazakhstan Cyprus Romania Lebanon Czech Republic Serbia Mongolia Denmark Slovakia Philippines Finland Slovenia Russia France Spain Singapore Georgia Sweden Syria Germany Switzerland Vietnam Greece Turkey Hungary UK Ireland Ukraine Africa Egypt Kenya IST Austria scientists by nationality Libya Austria 14.7% Nigeria Germany 10.9% South America Italy 7.4% Argentina India 5.9% Russia 4.7% Brazil Slovakia 4.1% Chile China 4.1% Colombia Hungary 3.7% Peru Spain 3.3% Uruguay USA 3.1% Czech Republic 2.9% UK 2.4% Oceania Other 32.8% Australia Content 2 HAPPY BIRTHDAY! 40 RESEARCH 4 Foreword by the president 42 Biology 5 Board member voices 44 Computer science 6 “An Austrian miracle” 46 Mathematics A year of celebration 48 Neuroscience
    [Show full text]
  • Second RAS Initiative Symposium Sponsored by the National Cancer Institute Advanced Technology Research Facility, Frederick, MD December 6-8, 2017
    The Second RAS Initiative Symposium Sponsored by the National Cancer Institute Advanced Technology Research Facility, Frederick, MD December 6-8, 2017 December 6 8:00 am – 8:15 am Welcome from the NCI Director Norman Sharpless 8:15 am – 9:00 am Keynote Frank McCormick (RAS Initiative, University of California, San Francisco) 9:00 am – 9:30 am Organoids as Model Systems for Tumorigenesis Calvin Kuo (Stanford University) 9:30 am – 9:50 am Break 9:50 am – 12:10 pm Activated RAS and Oncogenesis - Chair: Jeff Settleman Douglas Lowy (National Cancer Institute) Christopher Counter (Duke University) Matthew Vander Heiden (Massachusetts Institute of Technology) Marie Evangelista (Genentech) Aaron Hobbs (Der Lab, University of North Carolina, Chapel Hill) 12:10 pm – 1:10 pm Lunch on your own 1:10 pm – 3:15 pm Poster Session #1 3:15 pm – 4:15 pm RAS Multimers at the Membrane - Chair: John Hancock Yao-Cheng Li (Wahl Lab, Salk Institute) Margie Sutton (Bast Lab, MD Anderson) Chiara Ambrogio (Jänne Lab, Dana Farber Cancer Institute) 4:15 pm – 5:30 pm RAS Membrane Modeling and Dynamics - Chair: Dwight Nissley Roland Winter (Technische Universität Dortmund) Fred Streitz (Lawrence Livermore National Laboratory) Chris Neale (Garcia Lab, Los Alamos National Laboratory) Walkersville Social Hall 79 West Frederick Street, Walkersville 6:15 – 7:00 pm Hors d’oeuvres, cash bar 7:00 pm Dinner December 7 8:00 am – 10:00 am Tumor Dynamics - Chair: Rosalie Sears Dafna Bar-Sagi (New York University) David Tuveson (Cold Spring Harbor Laboratory) Channing Der (University
    [Show full text]